Sign In
Buy DIOD
$116.22
+2.09 (+1.83%)
At Close: Jun 03, 2026
Were Hedge Funds Right About Buying Gilead Sciences, Inc. (GILD)?
05:16pm, Monday, 29'th Jun 2020
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of Ma
Gilead Sets a Good-Enough Bar With Covid-Treatment Price
04:59pm, Monday, 29'th Jun 2020
(Bloomberg Opinion) -- Pricing a new medicine aimed at taming a pandemic is one of the touchiest scenarios imaginable for a drug company. Set the price too high, and the world will assail you for pr
Gilead Sets Pricing For Remdesivir Drug Candidate At $2,340 Per Patient
04:17pm, Monday, 29'th Jun 2020
Gilead Sciences Inc. (GILD) on Monday priced its experimental coronavirus drug candidate remdesivir at $2,340 per patient for a 5-day treatment in the U.S. and other developed countries.The price for
Gilead prices COVID-19 drug Remdesivir at over $3,000 with insurance
03:37pm, Monday, 29'th Jun 2020
As the country begins to pullback on reopenings, U.S. coronavirus cases continue to surge. Yahoo Finance’s Anjalee Khemlani weighs in.
US STOCKS-Wall St gains as investors pin hope on stimulus-powered rebound
02:56pm, Monday, 29'th Jun 2020
Wall Street's main indexes inched up on Monday following a sharp selloff last week, as investors clung to hopes of a stimulus-backed economic rebound even as coronavirus cases surged, while a jump in
Gilead prices remdesivir at $2,340 for treatment in most of the developed world
02:47pm, Monday, 29'th Jun 2020
Shares of Gilead Sciences Inc. gained 1.1% in premarket trading on Monday after the drugmaker disclosed that remdesivir, its experimental COVID-19 treatment, will cost $2,340 for a course of treatmen
HHS: 500,000 courses of Gilead Sciences' remdesivir to be available for sale
02:42pm, Monday, 29'th Jun 2020
Health officials said Monday that it will receive 500,000 treatment courses of Gilead Sciences Inc.'s remdesivir through September that can then be purchased by U.S. hospitals. Gilead in May received
Major indices open mixed amid a surge in coronavirus cases
01:51pm, Monday, 29'th Jun 2020
Mike Ryan, UBS Wealth Management Americas Chief Investment Officer, Yahoo Finance’s Brian Sozzi and Jared Blikre to discuss the latest market action.
Covid Changed the Definition of Corporate Leadership. Meet Barron’s New Top CEOs.
01:36pm, Monday, 29'th Jun 2020
In a Conference Board survey, U.S. chiefs cited the possibility of a recession as their top concern for this year. In March, the global pandemic shut down entire industries overnight. None of this h
‘The second wave may be even worse because people may not follow the requirements’: Dr. Kass
01:23pm, Monday, 29'th Jun 2020
On Monday, Gilead Sciences announced that it would charge more than $2,340 for the use of its remdesivir per patient. Dr Dara Kass, Associate Professor of Emergency Medicine at Columbia University Med
JPMorgan Chase & Co. Sells 112,998 Shares of Diodes Incorporated (NASDAQ:DIOD)
06:06am, Friday, 26'th Jun 2020
JPMorgan Chase & Co. lessened its holdings in shares of Diodes Incorporated (NASDAQ:DIOD) by 82.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The inst
Diodes (NASDAQ:DIOD) Rating Lowered to Sell at Zacks Investment Research
01:36am, Friday, 26'th Jun 2020
Diodes (NASDAQ:DIOD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, “Dio
Drug pricing review group raises recommended price for Gilead's remdesivir
03:35pm, Wednesday, 24'th Jun 2020India's Hetero prices experimental COVID-19 drug remdesivir at $71 per 100 mg vial
11:18am, Wednesday, 24'th Jun 2020
India's Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at 5,400 rupees ($71) per 100-milligram vial, the drugmaker said on Wednesday, as it prepares
Gilead To Acquire Stake in Cancer Drug Developer Pionyr For $275 Million
07:59pm, Tuesday, 23'rd Jun 2020
Gilead Sciences Inc. (GILD) announced on Tuesday that it will buy a 49.9% equity stake in Pionyr Immunotherapeutics Inc., for $275 million.Under the terms of the deal, Gilead has an exclusive option t
